Paper Details

  1. Home
  2. Paper Details

Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.

Author: , BrigantiAlberto, BryniarskiPiotr, CompératEva, D'AmicoAnthony V, GandagliaGiorgio, JoniauSteven, LaukhtinaEkaterina, LeapmanMichael S, MassardChristophe, MerseburgerAxel S, MoriKeiichiro, MostafaeiHadi, PloussardGuillaume, PradereBenjamin, QuhalFahad, RajwaPawel, RoubaudGuilhem, SaadFred, ShariatShahrokh F, ShimSung Ryul, SprattDaniel E, TsaurIgor, YanagisawaTakafumi, van den BerghRoderick C N

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Intensifying systemic therapy with docetaxel or an androgen receptor signaling inhibitor (ARSI) in addition to androgen deprivation therapy (ADT) improves outcomes in high-risk nonmetastatic prostate cancer patients treated with local definitive therapy. ARSI+ADT outperformed docetaxel+ADT for survival endpoints and had a more favorable adverse event profile.
Paper Details　
Original Abstract of the Article :
CONTEXT: Several recent randomised trials have evaluated the role of combination systemic treatment using androgen deprivation therapy (ADT) plus chemotherapy or an androgen receptor signaling inhibitor (ARSI) in patients with high-risk and/or unfavourable nonmetastatic prostate cancer (nmPC). OBJE...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.eururo.2022.03.031

データ提供：米国国立医学図書館（NLM）

Intensifying Therapy for Unfavorable Prostate Cancer

The field of [prostate cancer treatment] is constantly evolving, seeking to optimize treatment strategies for patients with various risk factors. This study investigates the impact of [intensifying systemic therapy] in addition to [definitive local treatment] for patients with [high-risk and/or unfavorable nonmetastatic prostate cancer (nmPC)]. The researchers conducted a systematic review and meta-analysis of clinical trials to evaluate the benefits of combining [androgen deprivation therapy (ADT)] with either [chemotherapy] or an [androgen receptor signaling inhibitor (ARSI)].

Intensifying Therapy for Unfavorable Prostate Cancer: Positive Results

The meta-analysis revealed that adding docetaxel to ADT in patients undergoing either [radical prostatectomy (RP)] or [radiation therapy (RT)] resulted in improved outcomes, particularly in [cancer-specific survival (CSS), metastasis-free survival (MFS), and failure-free survival (FFS)]. The authors found that for patients treated with RT alone, docetaxel-based combination therapy did not meet the significance threshold for OS, CSS, or MFS, but the difference for FFS was statistically significant. Network meta-analyses including RT studies showed that ARSI + ADT outperformed docetaxel + ADT for survival endpoints and had a more favorable AE profile.

Prostate Cancer: Understanding Treatment Options and Risk Factors

If you are diagnosed with prostate cancer, consult with your doctor to discuss the available treatment options and develop a personalized treatment plan. Understanding your risk factors and the potential benefits and risks of various therapies is crucial for making informed decisions about your health.

Dr. Camel’s Conclusion

This comprehensive meta-analysis provides valuable evidence supporting the benefits of intensifying systemic therapy in patients with unfavorable prostate cancer. The findings suggest that combining ADT with either docetaxel or an ARSI can improve oncologic outcomes, particularly in patients undergoing RT. The authors’ call for personalized treatment approaches based on patient characteristics and risk factors is crucial in optimizing treatment effectiveness and improving patient outcomes.

Date :
  1. Date Completed 2022-06-14
  2. Date Revised 2022-11-30
Further Info :

Pubmed ID

35465985

DOI: Digital Object Identifier

10.1016/j.eururo.2022.03.031

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.